Savvy Advisors Inc. Raises Position in Novo Nordisk A/S (NYSE:NVO)

Savvy Advisors Inc. raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 69.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,728 shares of the company’s stock after buying an additional 1,524 shares during the quarter. Savvy Advisors Inc.’s holdings in Novo Nordisk A/S were worth $444,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in NVO. Ashton Thomas Private Wealth LLC boosted its position in shares of Novo Nordisk A/S by 7.9% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 15,910 shares of the company’s stock valued at $1,894,000 after acquiring an additional 1,165 shares during the last quarter. Verus Capital Partners LLC lifted its position in Novo Nordisk A/S by 27.6% during the third quarter. Verus Capital Partners LLC now owns 6,509 shares of the company’s stock valued at $775,000 after purchasing an additional 1,408 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its stake in Novo Nordisk A/S by 57.8% in the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 10,275 shares of the company’s stock worth $1,243,000 after buying an additional 3,762 shares in the last quarter. Apollon Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 2.4% in the 3rd quarter. Apollon Wealth Management LLC now owns 38,835 shares of the company’s stock worth $4,624,000 after buying an additional 906 shares during the last quarter. Finally, Buckingham Capital Management Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $3,874,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.9 %

NVO opened at $107.05 on Wednesday. The company has a market cap of $480.39 billion, a P/E ratio of 34.64, a P/E/G ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The business’s 50-day moving average price is $120.82 and its 200-day moving average price is $130.22. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Analysts Set New Price Targets

Several research analysts recently issued reports on NVO shares. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.